Mirum Pharmaceuticals CEO sells 20,000 shares

The sale was reported under a Rule 10b5-1 plan adopted by the CEO on March 2, 2026.

Available on EDGAR 11/04/2026 - 08:48 PM EST Accepted by SEC EDGAR 11/04/2026 - 08:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. Chief Executive Officer Christopher Peetz reported exercising fully vested options for 20,000 common shares at $2.936 per share and selling 20,000 shares at $90 per share on November 4, 2026. The sale was made under a Rule 10b5-1 plan adopted on March 2, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 20,000 shares ($1.74M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Peetz Christopher

Role CHIEF EXECUTIVE OFFICER

Sold 20,000 shs ($1.80M)

Approx. gross sale proceeds $1.80M

Approx. exercise cost $59K

Approx. pre-tax spread $1.74M

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) F2	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$2.936	$59K
Sale	Common Stock F1	20,000	$90.00	$1.80M
Holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 38,487 contracts (Direct); Common Stock — 206,637 shares (Direct); Common Stock — 187,500 shares (Indirect, By The Peetz Family Trust)

Footnotes (2)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.
2. F2. The stock option is fully vested.

Key Figures

Options exercised: 20,000 options Exercise price: $2.936 per share Shares sold: 20,000 shares +3 more

6 metrics

Options exercised 20,000 options November 4, 2026

Exercise price $2.936 per share Options exercised November 4, 2026

Shares sold 20,000 shares November 4, 2026

Sale price $90 per share Shares sold November 4, 2026

Employee stock options after exercise 38,487 options Reported position following the November 4, 2026 exercise

Shares held by The Peetz Family Trust 187,500 shares Indirect holdings as of November 4, 2026

Key Terms

Rule 10b5-1 Plan, Employee Stock Option (right to buy), fully vested

3 terms

Rule 10b5-1 Plan regulatory

"pursuant to a Rule 10b5-1 Plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

fully vested financial

"The stock option is fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MIRM shares did Christopher Peetz sell, and at what price?

Christopher Peetz sold 20,000 Mirum common shares at $90 per share on November 4, 2026. The sale was reported under a Rule 10b5-1 plan adopted on March 2, 2026.

How many employee stock options did MIRM CEO Christopher Peetz report after the exercise?

Christopher Peetz reported 38,487 employee stock options following the November 4, 2026 exercise. The reported exercise covered 20,000 options, and the stock option was fully vested.

How many MIRM shares were held through Christopher Peetz's family trust?

The reported holdings list 187,500 shares of Mirum common stock held indirectly by The Peetz Family Trust as of November 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peetz Christopher

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2026		M		20,000	A	$2.936	226,637	D
Common Stock	11/04/2026		S(1)		20,000	D	$90	206,637	D
Common Stock								187,500	I	By The Peetz Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.936	11/04/2026		M			20,000	(2)	03/11/2029	Common Stock	20,000	$0	38,487	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026.

2. The stock option is fully vested.

	/s/ Judit Ryvkin, Attorney-in-Fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)